Biopharmaceutical company AbbVie (ABBV) saw its stock jump on Friday following the release of its Q1 2025 earnings report. The company reported adjusted diluted earnings per share of $2.46, compared to Wall Street’s estimate of $2.38. Its adjusted diluted EPS rose 6.5% year-over-year from $2.31.
The AbbVie earnings report also included revenue of $13.343 billion. Analysts expected the company to report revenue of $12.93 billion in Q1 2025. ABBV’s revenue grew 8.4% from the $12.31 billion reported in Q1 2024. Its revenue growth was fueled by strong gains from its Immunology, Neuroscience, and Oncology Portfolios, offsetting a drop from its Aesthetics Portfolio.
ABBV stock jumped 2.73% alongside its Q1 earnings beat, following a 1.88% rally yesterday, and adding to its 3.41% increase year-to-date.
AbbVie 2025 Guidance
The strong Q1 2025 earnings report had AbbVie reevaluate its guidance for 2025. It increased its adjusted diluted EPS outlook from between $11.99 and $12.19 to between $12.09 and $12.29. To put that in perspective, Wall Street’s adjusted diluted EPS estimate for 2025 is $12.18. AbbVie notes its outlook includes an unfavorable 13-cent impact from its Acquired IPR&D and Milestones Expense.
AbbVie CEO Robert Michael said, “The fundamentals of our business are strong and we continue to bolster our outlook with pipeline advancements and strategic investments. Based on the progress we are making, AbbVie is well positioned for the long term.”
Is ABBV Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for AbbVie is Moderate Buy, based on 13 Buy and five Hold ratings over the last three months. With that comes an average price target of $212, representing a potential 17.54% upside for ABBV stock. These ratings and price targets will likely change as analysts update their coverage after today’s earnings.
